Toll样受体7/8对肿瘤发生发展过程影响的研究进展

doi:10.13481/j.1671-587X.20260129

Abstract

Abstract:

Toll-like receptors （TLRs） are the most well-characterized family of pattern recognition receptors （PRRs）， playing key roles in both innate and adaptive immune processes. In addition to their widespread expression in immune cells， TLRs are also expressed in many tumor cell populations. Their activation can lead to tumor progression or regression， which has made the clinical relevance of TLRs to tumors a research hotspot in recent years. Among them， the TLR subtypes TLR7/8 have dual effects in tumorigenesis and development. On the one hand， they exert tumor-suppressive effects by inducing effective anti-tumor immune responses and mediating tumor cell death； on the other hand， they can also promote tumor progression by regulating tumor cell behavior and the tumor microenvironment （TME）. Therefore， TLR7/8 has become a potential target for tumor prevention and treatment. This article summarizes and analyzes the molecular characteristics and signaling pathways of TLR7/8 and their impact on the process of tumorigenesis and development based on the latest research findings at home and abroad， and systematically reviews the research progress in the application of small molecule modulators targeting TLR7/8， aiming to provide a reference for the discussion on the role of TLR7/8 in tumor prevention and treatment.

Key words: Toll-like receptor 7/8, Neoplasm, Biological function, Small molecule modulator, Tumor microenvironment, Innate immune response

CLC Number:

R730.51

Luyao WANG,Chenxi ZHAO,Jincheng DU,Linlin LIU. Research progress in effect of Toll-like receptor 7/8 on occurrence and development of tumor[J].Journal of Jilin University(Medicine Edition), 2026, 52(1): 264-271.

References 65

[1]	ZHANG E J， MA Z Y， LU M J. Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases［J］. Cell Mol Life Sci， 2022， 79（11）： 547.
[2]	KAWASAKI T， KAWAI T. Toll-like receptor signaling pathways［J］. Front Immunol， 2014， 5： 461.
[3]	RAKOFF-NAHOUM S， MEDZHITOV R. Toll-like receptors and cancer［J］. Nat Rev Cancer， 2009， 9（1）： 57-63.
[4]	BEHZADI P， GARCÍA-PERDOMO H A， KARPIŃSKI T M. Toll-like receptors： general molecular and structural biology［J］. J Immunol Res， 2021， 2021： 9914854.
[5]	BAYRAKTAR R， BERTILACCIO M T S， CALIN G A. The interaction between two worlds： microRNAs and toll-like receptors［J］. Front Immunol， 2019， 10： 1053.
[6]	ASAMI J， SHIMIZU T. Structural and functional understanding of the toll-like receptors［J］. Protein Sci， 2021， 30（4）： 761-772.
[7]	CHEN L F， ZHENG L L， CHEN P Q， et al. Myeloid differentiation primary response protein 88 （MyD88）： the central hub of TLR/IL-1R signaling［J］. J Med Chem， 2020， 63（22）： 13316-13329.
[8]	DUAN T H， DU Y， XING C S， et al. Toll-like receptor signaling and its role in cell-mediated immunity［J］. Front Immunol， 2022， 13： 812774.
[9]	URBAN-WOJCIUK Z， KHAN M M， OYLER B L， et al. The role of TLRs in anti-cancer immunity and tumor rejection［J］. Front Immunol， 2019， 10： 2388.
[10]	PRADERE J P， DAPITO D H， SCHWABE R F. The Yin and Yang of toll-like receptors in cancer［J］. Oncogene， 2014， 33（27）： 3485-3495.
[11]	WOLSKA A， LECH-MARAŃDA E， ROBAK T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment［J］. Cell Mol Biol Lett， 2009， 14（2）： 248-272.
[12]	ROLFO C， GIOVANNETTI E， MARTINEZ P， et al. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer［J］. NPJ Precis Oncol， 2023， 7（1）： 26.
[13]	CHEN J Q， SZODORAY P， ZEHER M. Toll-like receptor pathways in autoimmune diseases［J］. Clin Rev Allergy Immunol， 2016， 50（1）： 1-17.
[14]	FITZGERALD K A， KAGAN J C. Toll-like receptors and the control of immunity［J］. Cell， 2020， 180（6）： 1044-1066.
[15]	TANJI H， OHTO U， SHIBATA T， et al. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands［J］. Science， 2013， 339（6126）： 1426-1429.
[16]	ZHANG Z K， OHTO U， SHIBATA T， et al. Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA［J］. Immunity， 2016， 45（4）： 737-748.
[17]	TANJI H， OHTO U， SHIBATA T， et al. Toll-like receptor 8 senses degradation products of single-stranded RNA［J］. Nat Struct Mol Biol， 2015， 22（2）： 109-115.
[18]	ZHANG Z K， OHTO U， SHIBATA T， et al. Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands［J］. Cell Rep， 2018， 25（12）： 3371-3381.
[19]	JURK M， HEIL F， VOLLMER J， et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848［J］. Nat Immunol， 2002， 3（6）： 499.
[20]	VASILAKOS J P， TOMAI M A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants［J］. Expert Rev Vaccines， 2013， 12（7）： 809-819.
[21]	KAWAI T， AKIRA S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity［J］. Immunity， 2011， 34（5）： 637-650.
[22]	O’NEILL L A J， BOWIE A G. The family of five： TIR-domain-containing adaptors in Toll-like receptor signalling［J］. Nat Rev Immunol， 2007， 7（5）： 353-364.
[23]	TAN Y H， KAGAN J C. Innate immune signaling organelles display natural and programmable signaling flexibility［J］. Cell， 2019， 177（2）： 384-398.e11.
[24]	KAWAI T， AKIRA S. TLR signaling［J］. Semin Immunol， 2007， 19（1）： 24-32.
[25]	KAWAI T， AKIRA S. Signaling to NF-kappaB by Toll-like receptors［J］. Trends Mol Med， 2007， 13（11）： 460-469.
[26]	WEST A P， KOBLANSKY A A， GHOSH S. Recognition and signaling by Toll-like receptors［J］. Annu Rev Cell Dev Biol， 2006， 22： 409-437.
[27]	LI S， STRELOW A， FONTANA E J， et al. IRAK-4： a novel member of the IRAK family with the properties of an IRAK-kinase［J］. Proc Natl Acad Sci USA， 2002， 99（8）： 5567-5572.
[28]	FERRAO R， ZHOU H， SHAN Y B， et al. IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly［J］. Mol Cell， 2014， 55（6）： 891-903.
[29]	LIN S C， LO Y C， WU H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling［J］. Nature， 2010， 465（7300）： 885-890.
[30]	SUN J， LI N， OH K S， et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use［J］. Sci Signal， 2016， 9（409）： ra3.
[31]	PEREIRA M， GAZZINELLI R T. Regulation of innate immune signaling by IRAK proteins［J］. Front Immunol， 2023， 14： 1133354.
[32]	CHEN Z J. Ubiquitination in signaling to and activation of IKK［J］. Immunol Rev， 2012， 246（1）： 95-106.
[33]	LIU T， ZHANG L Y， JOO D， et al. NF-κB signaling in inflammation［J］. Signal Transduct Target Ther， 2017， 2： 17023.
[34]	LITVAK V， RAMSEY S A， RUST A G， et al. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals［J］. Nat Immunol， 2009， 10（4）： 437-443.
[35]	IWASAKI A， MEDZHITOV R. Toll-like receptor control of the adaptive immune responses［J］. Nat Immunol， 2004， 5（10）： 987-995.
[36]	YANG Y， FENG R， WANG Y Z， et al. Toll-like receptors： Triggers of regulated cell death and promising targets for cancer therapy［J］. Immunol Lett， 2020， 223： 1-9.
[37]	RIDNOUR L A， CHENG R Y， SWITZER C H， et al. Molecular pathways： toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity［J］. Clin Cancer Res， 2013， 19（6）： 1340-1346.
[38]	PALUCKA K， BANCHEREAU J. Cancer immunotherapy via dendritic cells［J］. Nat Rev Cancer， 2012， 12（4）： 265-277.
[39]	WU J， LI S， YANG Y， et al. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo ［J］. Oncotarget， 2017， 8（7）： 11708-11718.
[40]	LU H L， DIETSCH G N， MATTHEWS M H， et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC［J］. Clin Cancer Res， 2012， 18（2）： 499-509.
[41]	VENEZIANI I， ALICATA C， MORETTA L， et al. Human toll-like receptor 8 （TLR8） in NK cells： Implication for cancer immunotherapy［J］. Immunol Lett， 2023， 261： 13-16.
[42]	ZHOU Z X， YU X， ZHANG J， et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma［J］. Cancer Lett， 2015， 369（2）： 298-306.
[43]	LEE M， PARK C S， LEE Y R， et al. Resiquimod， a TLR7/8 agonist， promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells［J］. Arch Pharm Res， 2014， 37（9）： 1234-1240.
[44]	SAFARZADEH E， MOHAMMADI A， MANSOORI B， et al. STAT3 silencing and TLR7/8 pathway activation repolarize and suppress myeloid-derived suppressor cells from breast cancer patients［J］. Front Immunol， 2020， 11： 613215.
[45]	ROUANET M， HANOUN N， LULKA H， et al. The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors［J］. Mol Ther， 2022， 30（4）： 1553-1563.
[46]	YEH D W， HUANG L R， CHEN Y W， et al. Interplay between inflammation and stemness in cancer cells： the role of toll-like receptor signaling［J］. J Immunol Res， 2016， 2016： 4368101.
[47]	LI W， ZHANG L Y， GUO B B， et al. Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma［J］. Mol Cancer， 2019， 18（1）： 22.
[48]	CHERFILS-VICINI J， PLATONOVA S， GILLARD M， et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance［J］. J Clin Invest， 2010， 120（4）： 1285-1297.
[49]	GRIMMIG T， MATTHES N， HOELAND K， et al. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer［J］. Int J Oncol， 2015， 47（3）： 857-866.
[50]	YE J， MA C L， HSUEH E C， et al. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence［J］. EMBO Mol Med， 2014， 6（10）： 1294-1311.
[51]	DAJON M， IRIBARREN K， PETITPREZ F， et al. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells［J］. Oncoimmunology， 2019， 8（1）： e1505174.
[52]	SIDBURY R， NEUSCHLER N， NEUSCHLER E， et al. Topically applied imiquimod inhibits vascular tumor growth in vivo ［J］. J Invest Dermatol， 2003， 121（5）： 1205-1209.
[53]	MORADI-MARJANEH R， HASSANIAN S M， HASANZADEH M， et al. Therapeutic potential of toll-like receptors in treatment of gynecological cancers［J］. IUBMB Life， 2019， 71（5）： 549-564.
[54]	ZHANG L， JING D， WANG L， et al. Unique photochemo-immuno-nanoplatform against orthotopic xenograft oral cancer and metastatic syngeneic breast cancer［J］. Nano Lett， 2018， 18（11）： 7092-7103.
[55]	PATINOTE C， KARROUM N B， MOARBESS G， et al. Agonist and antagonist ligands of toll-like receptors 7 and 8： Ingenious tools for therapeutic purposes［J］. Eur J Med Chem， 2020， 193： 112238.
[56]	RYNN C， UMEHARA K， JIANG T Y， et al. A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929， an oral prodrug of a targeted cancer immunotherapy TLR7 agonist［J］. Xenobiotica， 2022， 52（8）： 855-867.
[57]	ZUO X Y， CHENG Q P， WANG Z M， et al. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer［J］. Int Immunopharmacol， 2024， 137： 112478.
[58]	MONK B J， FACCIABENE A， BRADY W E， et al. Integrative development of a TLR8 agonist for ovarian cancer chemoimmunotherapy［J］. Clin Cancer Res， 2017， 23（8）： 1955-1966.
[59]	FERRIS R L， SABA N F， GITLITZ B J， et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck： the Active8 randomized clinical trial［J］. JAMA Oncol， 2018， 4（11）： 1583-1588.
[60]	DIETSCH G N， RANDALL T D， GOTTARDO R， et al. Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod （VTX-2337）［J］. Clin Cancer Res， 2015， 21（24）： 5445-5452.
[61]	CHENG Y W， BORCHERDING N， OGUNSAKIN A， et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent［J］. Sci Rep， 2021， 11（1）： 1535.
[62]	WANG Y X， YANG H P， LI H P， et al. Development of a novel TLR8 agonist for cancer immunotherapy［J］. Mol Biomed， 2020， 1（1）： 6.
[63]	ROOK A H， GELFAND J M， WYSOCKA M， et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma［J］. Blood， 2015， 126（12）： 1452-1461.
[64]	ZHANG S， HU Z， TANJI H， et al. Structural basis for small-molecule inhibition of toll-like receptor 8［J］. Nat Chem Biol， 2018， 14： 58-64.
[65]	MATBOLI M， HOSSAM N， FARAG D， et al. miRNAs： possible regulators of toll like receptors and inflammatory tumor microenvironment in colorectal cancer［J］. BMC Cancer， 2024， 24（1）： 824.

Research progress in effect of Toll-like receptor 7/8 on occurrence and development of tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 65

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Yuxin LI,Lu YANG,Fengjin LI,Ling QI. Inductive effect of wedelolactone on cuproptosis in human pancreatic cancer PANC-1 cells [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 182-191.
[2]	Shanshan SUN,Mei LU,Xinfu GAO,LYu Guangyao,Baolei Zhao,LYu Wenwen. Inhibitory effect of Bradykinin 1 receptor antagonist ELN441958 on proliferation of HepG2 cells by regulating Akt/FoxO3a signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 70-80.
[3]	Renyi YANG,Jincheng TANG,Kexiong LI,Wei PENG,Zhuo LIU,Ling WU,Puhua ZENG. Temporal trends and attributable risk analysis of liver cancer burden in China from 1990 to 2021 [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 199-210.
[4]	Qiankun CHANG,Wenying WU,Chunqiang BAI,Zhichao DING,Weifang WANG,Minghan LIU. Predictive value of breast cancer related parameters combined with positive axillary lymphnode ultrasound features for lymphnode metastasis burden [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1670-1678.
[5]	Qiuyuan SU,Ling ZHAO,Jiajia TAN,Shien MO,Haiqin ZHOU,Fangfang LU,Yi WEI,Yang ZHOU,Yan KUANG. Construction of SPHK1 overexpression lentiviral vectors and establishment of stable transfected SKOV3 cell lines [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1709-1716.
[6]	Rongmian YAN,Xinting SUN,Xin GUAN,Yu CHENG,Liying HAN. Effects of KLK5 overexpression on growth of subcutaneous xenograft tumor and cisplatin sensitivity in nude mice [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1194-1203.
[7]	Pingsheng ZHU,Sitang GE,Lugen ZUO,Deli CHEN,Yangyang ZHANG. Effect of miR-325-3p targeting PRELID1 gene in regulation of EMT pathway on invasion and migration of colon cancer cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1185-1193.
[8]	Yunxiu XIA,Shuo ZHANG,Huanhai ZHANG,Fei WANG,Hongliang DONG,Jing DU. Long non-coding RNA LINC00973 promotes migration, invasion and distal metastasis of epithelial ovarian cancer and its molecular mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 866-878.
[9]	Xiaoshuang HE,Lina XU,Mei CUI,Yu ZHAO,Bei WANG,Zheng HUANG,Yuchao WANG,Wenyan XIN,Chao WU. Effects of lncRNA DUXAP8 in lung cancer A549 cells-derived exosomes on lung cancer cell growth and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 958-967.
[10]	Hongli LI,Mengyao WANG,Yangyang LIU,Hui ZHANG,Li LI. Effect of KHSRP on biological behavior of colorectal cancer cells through activation of JAK/STAT signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 996-1006.
[11]	Wengxiu GUO,Huiling ZHANG,Jun MENG. Research progress in structure and biological function of protein phosphatase 1 and its relationship with occurence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 822-830.
[12]	Mengyun LU,Yucheng HAN,Yihong HU,Minhui HE,Yanqun ZHANG,Xianqiong ZOU. Effects of glycolipid transfer protein on proliferation, migration，and invasion of pancreatic cancer PANC-1 cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 284-295.
[13]	Congcong BAI,Xianlei ZHOU,Zhi ZHANG,Shuang GAO,Xuemei ZHANG. Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 392-402.
[14]	Jing DENG,Xuan WANG,Changyu SHI,Siqi YANG,Qinling ZOU,Ming JIN. Effect of securinine on proliferation and apoptosis of human colon cancer SW620 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 307-316.
[15]	Yan WANG,Zouyu ZHAO,Panpan YU,Ping YANG. Expression of I kappa B kinase-interacting protein in cervical cancer tissue and its effect on proliferation, migration and invasion of cervical cancer cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 341-351.